Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Cowen 41st Annual Health Care Conference (Transcript)Seeking Alpha • 03/02/21
Regeneron's Single-Dose REGN1908-1909 Shows Rapid, Durable Benefit In Cat-Allergic Asthma PatientsBenzinga • 03/01/21
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild AsthmaPRNewsWire • 02/27/21
EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 PatientsPRNewsWire • 02/26/21
Regeneron To Stop Giving Placebo In COVID-19 Antibody Trial After 'Clear Efficacy'Benzinga • 02/25/21
Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11Benzinga • 02/23/21
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%GlobeNewsWire • 02/22/21
The $12 Billion Market That Has Biotech Stocks Hijacking The Immune SystemInvestors Business Daily • 02/12/21
U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent LitigationPRNewsWire • 02/11/21
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/05/21